Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Follicular
  • Neoplasm Recurrence, Local

abstract

  • In patients with FL who received first-line R-CHOP, POD within 2 years after diagnosis was associated with poor outcomes and should be further validated as a standard end point of chemoimmunotherapy trials of untreated FL. This high-risk FL population warrants further study in directed prospective clinical trials.

publication date

  • August 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4879714

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.59.7534

PubMed ID

  • 26124482

Additional Document Info

start page

  • 2516

end page

  • 22

volume

  • 33

number

  • 23